135 related articles for article (PubMed ID: 1376692)
21. Tumour markers in prostatic cancer.
Cooper EH
Scand J Clin Lab Invest Suppl; 1991; 206():42-51. PubMed ID: 1719610
[TBL] [Abstract][Full Text] [Related]
22. Serum prostatic acid phosphatase, gamma-seminoprotein and prostatic specific antigen in hemodialysis patients.
Sasagawa I; Nakada T; Hashimoto T; Ishigooka M; Kubota Y; Hirano K; Hirano J; Suzuki Y
Urol Int; 1992; 48(2):181-3. PubMed ID: 1374977
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic value of prostatic acid phosphatase and prostate-specific antigen in patients with prostatic cancer.
Pagani F; Zambolin T; Bonora R; Panteghini M
J Nucl Med Allied Sci; 1990; 34(4 Suppl):85-7. PubMed ID: 1709211
[TBL] [Abstract][Full Text] [Related]
24. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice.
Csapo Z; Brand K; Walther R; Fokas K
J Urol; 1988 Nov; 140(5):1032-8. PubMed ID: 2459419
[TBL] [Abstract][Full Text] [Related]
25. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
Amico S; Liehn JC; Desoize B; Larbre H; Deltour G; Valeyre J
Clin Nucl Med; 1991 Sep; 16(9):643-8. PubMed ID: 1718651
[TBL] [Abstract][Full Text] [Related]
26. Advanced prostate cancer follow-up with prostate-specific antigen, prostatic acid phosphatase, osteocalcin and bone isoenzyme of alkaline phosphatase.
Curatolo C; Ludovico GM; Correale M; Pagliarulo A; Abbate I; Cirrillo Marucco E; Barletta A
Eur Urol; 1992; 21 Suppl 1():105-7. PubMed ID: 1385127
[TBL] [Abstract][Full Text] [Related]
27. Prostate specific antigen and prostatic acid phosphatase measurements for the follow-up of patients with prostate cancer.
Mortarelli EA
Ann Clin Lab Sci; 1992; 22(4):201-6. PubMed ID: 1380223
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H
Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515
[TBL] [Abstract][Full Text] [Related]
29. [Clinical evaluation of serum basic fetoprotein for prostatic cancer--comparative study with PAP, gamma-Sm and PSA].
Gotoh A; Mizuno Y; Takenaka A; Gohji K; Ogawa T; Arakawa S; Kamidono S; Harada K; Nagata H; Hirooka K
Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):467-72. PubMed ID: 1712873
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
[TBL] [Abstract][Full Text] [Related]
31. Immunologically measured serum markers and their role in the management of prostate cancer.
Powell P; Neal D; Gibb I; Wilson L; Hall R
Eur Urol; 1988; 15(1-2):48-53. PubMed ID: 2463921
[TBL] [Abstract][Full Text] [Related]
32. [The role of PSA in prostatic adenocarcinoma].
Manca GP
Minerva Med; 1990 Apr; 81(4):261-4. PubMed ID: 1692981
[TBL] [Abstract][Full Text] [Related]
33. Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma.
Silver RI; Straus FH; Vogelzang NJ; Kellman H; Chodak GW
Urology; 1991 Jan; 37(1):17-21. PubMed ID: 1702566
[TBL] [Abstract][Full Text] [Related]
34. Is acid phosphatase (PAP) still justified in the management of prostatic cancer?
Kontturi M
Acta Oncol; 1991; 30(2):169-70. PubMed ID: 1709356
[TBL] [Abstract][Full Text] [Related]
35. The contribution of prostatic acid phosphatase and prostatic specific antigen in the diagnosis of prostatic cancer.
van Dalen A; Helmhout DH; van Caubergh RD
Int J Biol Markers; 1988; 3(2):123-6. PubMed ID: 2468722
[TBL] [Abstract][Full Text] [Related]
36. A comparative study on the diagnostic value of prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) in patients with carcinoma of the prostate gland.
van Dieijen-Visser MP; Delaere KP; Gijzen AH; Brombacher PJ
Clin Chim Acta; 1988 May; 174(2):131-40. PubMed ID: 2454767
[TBL] [Abstract][Full Text] [Related]
37. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
Morote Robles J; de Torres Mateos JA
Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148
[TBL] [Abstract][Full Text] [Related]
38. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
Beacock CJ; Buck AC; Zwinck R; Peeling WB; Rees RW; Turkes A; Walker K; Griffiths K
Br J Urol; 1987 May; 59(5):436-42. PubMed ID: 2954605
[TBL] [Abstract][Full Text] [Related]
39. [Changes in prostatic acid phosphatase, gamma-seminoprotein and prostate specific antigen after endocrine therapy for stage D2 prostate cancer].
Akimoto S; Akakura K; Masai M; Isaka S; Shimazaki J
Hinyokika Kiyo; 1990 Jul; 36(7):783-91. PubMed ID: 1700588
[TBL] [Abstract][Full Text] [Related]
40. Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma.
Desoize B; Amico S; Larbre H; Coninx P; Jardillier JC
Clin Biochem; 1991 Oct; 24(5):443-6. PubMed ID: 1760884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
